Drug updated on 3/28/2024
| Dosage Form | Tablets (oral; 10 mg, 20 mg) |
| Drug Class | Non-steroidal mineralocorticoid receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Summary
- Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.
- A total of 15 systematic reviews/meta-analyses were reviewed to gather information about this drug's efficacy and safety profile.
- The documents highlight that finerenone significantly reduces the risk of major adverse cardiac events such as myocardial infarction and all-cause mortality compared to placebo.
- Compared to other mineralocorticoid receptor antagonists like spironolactone and eplerenone, finerenone shows a comparable or even better efficacy profile especially in reducing heart failure hospitalizations and cardiovascular mortality.
- In terms of renal outcomes including urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), finerenone demonstrates robust reno-protective effects in patients with type 2 diabetes mellitus associated with chronic kidney disease.
- Despite its benefits, an elevated risk for hyperkalemia has been noted among patients treated with finerenon; however it appears manageable when compared against some steroidal MRAs' side effect profiles.
- Apart from hyperkalemia incidence which was higher than placebo group's rates, overall adverse event profile seems consistent between both groups indicating good tolerability for this drug amongst users.
- While specific subgroup analyses are not detailed within these studys, general findings suggest potential widespread applicability across CKD/T2D population without significant differences based on age, race or gender.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Kerendia (finerenone) Prescribing Information. | 2022 | Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). | 2023 | Clinical Kidney Journal |
| Finerenone added to treatment guidelines for type 2 diabetes and chronic kidney disease. | 2023 | American Journal of Nursing |
| Clinical implications and guidelines for CKD in type 2 diabetes. | 2023 | Nephrology Dialysis Transplantation |